论文部分内容阅读
自1980年2月至1988年10月,对全部组织学诊断肝硬化的患者作预防性硬化治疗试验。研究对象需符合下列标准:①内镜食管静脉曲张大至足能进行静脉曲张内注射;②过去无静脉曲张出血;③年龄在18～70岁间;①HBsAg 阴性;⑤目前无服用β-受体阻滞剂。测定肝静脉楔压,如楔压<12mmHg 被认为出血的危险性相对较小,根据肝脏病情况经常随访,如楔压≥12mmHg 就认为确有出血的危险,即随机分为注射和非注射组进行预防性硬化治疗,以5%乙醇作内镜下食管静脉曲张内注射。每隔三周重
From February 1980 to October 1988, all patients with histologically diagnosed cirrhosis were treated for prophylactic sclerotherapy. Subjects should meet the following criteria: ① endoscopic esophageal varicose vein large enough to carry out varicose veins; ② no past varicose bleeding; ③ aged 18 to 70 years old; ① HBsAg negative; ⑤ no taking beta-receptor Blockers. Determination of hepatic venous wedge pressure, such as wedge pressure <12mmHg is considered to be relatively less risk of bleeding, liver disease often follow-up, such as wedge pressure ≥ 12mmHg think there is indeed the risk of bleeding, that is randomly divided into injection and non-injection group Preventive sclerosis treatment, 5% ethanol for endoscopic esophageal varices. Heavy every three weeks